Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Common Equity (2016 - 2025)

Altimmune (ALT) has disclosed Common Equity for 16 consecutive years, with $185.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 39.16% to $185.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $185.6 million, a 39.16% increase, with the full-year FY2024 number at $123.5 million, down 36.37% from a year prior.
  • Common Equity was $185.6 million for Q3 2025 at Altimmune, up from $161.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $246.4 million in Q1 2021 to a low of $123.5 million in Q4 2024.
  • A 5-year average of $179.9 million and a median of $184.9 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 488.2% in 2021, then crashed 36.37% in 2024.
  • Altimmune's Common Equity stood at $199.1 million in 2021, then fell by 6.95% to $185.3 million in 2022, then increased by 4.75% to $194.1 million in 2023, then plummeted by 36.37% to $123.5 million in 2024, then surged by 50.27% to $185.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Common Equity are $185.6 million (Q3 2025), $161.4 million (Q2 2025), and $142.2 million (Q1 2025).